- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06166472 | A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor | unknown | Phase 1 | 72 | AkesoINDUSTRY | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 |
| clinicaltrials |
| NCT05886374 | A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 81 | HutchmedINDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05396339 | A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 120 | SUNHO(China)BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05911984 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 27 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04571892 | A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 58 | Shanghai East HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05539157 | Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | unknown | Phase 1 | 1 | Immorna Biotherapeutics, Inc.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05338957 | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 30 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03792958 | Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 19 | AnewPharmaINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05508620 | A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 270 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05478785 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05441046 | Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 120 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | unknown | Phase 1 | 113 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT03662815 | Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04981691 | Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors(Amaretto) | unknown | Phase 1 | 12 | Ruijin HospitalOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04864379 | Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors | unknown | Phase 1 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04758897 | Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 18 | CNBG-Virogin Biotech (Shanghai) Ltd.INDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04226066 | Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 69 | Tasly Tianjin Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04275050 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 19, 2020 | clinicaltrials |
| NCT03618043 | Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer | unknown | Phase 1 | 14 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT03171220 | Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors(NRT-01) | unknown | Phase 1 / Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01694472 | Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors | unknown | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 22, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Dec 12, 2023source: clinicaltrials